-
09:10:39 PM

ATHA Stock News

11/29/22 11:00 AM
Nasdaq : ATHA
clinical trial
Athira Pharma Highlights Therapeutic Potential of Fosgonimeton in Presentation of Additional Biomarker Data in Mild-to-Moderate Alzheimer’s Disease Patients from ACT-AD Phase 2 Study at CTAD Conference
Fosgonimeton treatment-related reductions in biomarkers of neurodegeneration (NfL) and neuroinflammation (GFAP) significantly correlated with improvements in clinical outcomes as assessed by the GST, a composite score of cognition (ADAS-Cog11) and function (ADCS-ADL23) Data demonstrate fosgonimeton
RHEA-AI
positive
10/17/22 7:00 AM
Nasdaq : ATHA
clinical trial
Athira Pharma Advances Phase 2/3 LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients Following Independent, Unblinded Interim Analysis
Results support potential clinically meaningful activity of fosgonimeton without background therapy and mitigate program risk Updated study well powered for primary endpoint with addition of fewer than 150 patients Company targets completion of enrollment in mid-2023 and topline results in early
RHEA-AI
positive